Robert Kayser, MD
Interventional Cardiology · Sea Girt, NJNPI 1346260999
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $29,745 of the $38,789 with a category attached, or 76.7%. Johnson & Johnson accounts for 83.1% of it on its own, with 44 other manufacturers making up the rest. Reporting peaked in 2019 at $13,057 and has fallen 91.9% since, to $1,060 in 2025.
Across 537 payments — averaging $72.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$32K
- Novartis$876
- AstraZeneca$755
- Medtronic$575
- Actelion Pharmaceuticals US, Inc.$511
- Abbott$491
- plus $3K from 39 others
Across 13 payments — averaging $234.48 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biotronik Inc.$3K
What the payments were for
- Consulting fees$3001%
- Speaking & faculty fees$29,74577%
- Travel & lodging$6252%
- Food & beverage$8,07521%
- Education$440%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$30,670
- FARXIGA$284
- BRILINTA$284
- SYMPLICITY G3$267
- AVEIR$252
- RESONATE$227
- FFRangio$140
- Impella$129
- Peripheral Orbital Atherectomy System$104
How this compares
$38,789 in reported general payments places this provider in the 80th percentile of 166 interventional cardiology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 784 | $992,135 |
| EliquisApixaban | 410 | $547,786 |
| Repatha SureclickEvolocumab | 478 | $393,799 |
| OpsumitMacitentan | 23 | $290,342 |
| UptraviSelexipag | 12 | $279,739 |
| EntrestoSacubitril/Valsartan | 165 | $251,707 |
| Orenitram ErTreprostinil Diolamine | 24 | $160,839 |
| AdempasRiociguat | 11 | $151,748 |
| FarxigaDapagliflozin Propanediol | 93 | $121,196 |
| MultaqDronedarone Hcl | 53 | $89,049 |
| Praluent PenAlirocumab | 134 | $77,473 |
| JardianceEmpagliflozin | 50 | $76,226 |
| BrilintaTicagrelor | 68 | $50,821 |
| Icosapent Ethyl | 81 | $35,141 |
| VascepaIcosapent Ethyl | 42 | $25,946 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $32,252 | $992,135784 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi | $511 | $570,08135 claims |
| PfizerEliquis | $223 | $547,786410 claims |
| NovartisEntresto | $876 | $251,707165 claims |
| AstraZenecaFarxiga, Brilinta | $755 | $172,017161 claims |
| BayerAdempas | $95 | $151,74811 claims |
| Sanofi-aventis U.S. LLCMultaq | $231 | $89,04953 claims |
| Boehringer IngelheimJardiance | $185 | $76,22650 claims |
| Novo NordiskWegovy | $92 | $25,73918 claims |
| Arbor Pharmaceuticals, Inc.Edarbyclor, Edarbi | $28 | $19,59729 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 166 interventional cardiology providers in New Jersey.
Other interventional cardiology in Sea Girt
- Ankitkumar PatelGlen Ridge$408K
- Ziad AbbudOcean$360K
- Ramin HastingsHasbrouck Heights$295K
- Michael LimHackensack$215K
- Darshan GodkarCedar Knolls$194K
- Ryan KapleHackensack$178K
- Matthew SayboltEatontown$175K
- Daniel KissEatontown$172K
- Kintur SanghviBordentown$139K
- Dimitrios KarmpaliotisMorristown$129K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.